| Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C0001792> <https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C0026062> <https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C0034782> <https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C0037080> <https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C0037083> <https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C0086287> <https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C0086418> <https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C0086582> <https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C0086982> <https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C0205847> <https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C0521117> <https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C1332653> <https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C1433141> <https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C3494263> <https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C4318440> <https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C4505319> <https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C5203670> <https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C5203676> <https://research.tib.eu/covid-19/entity/35121493_HAS_TOPIC_C5392141>
?:authorAffiliation	[\'Vanda Pharmaceuticals Inc, Washington, DC, USA. Electronic address: sandra.smieszek@vandapharma.com.\', \'Vanda Pharmaceuticals Inc, Washington, DC, USA.\']
?:citedBy	-1
?:creator	<https://research.tib.eu/covid-19/entity/Birznieks_Gunther> <https://research.tib.eu/covid-19/entity/Polymeropoulos_Christos_M> <https://research.tib.eu/covid-19/entity/Polymeropoulos_Mihael_H> <https://research.tib.eu/covid-19/entity/Polymeropoulos_Vasilios_M> <https://research.tib.eu/covid-19/entity/Przychodzen_Bartlomiej_P> <https://research.tib.eu/covid-19/entity/Smieszek_Sandra_P>
?:doi	S1043-4666(22)00019-910.1016/j.cyto.2022.155810
?:doi	<https://research.tib.eu/covid-19/entity/S1043-4666%2822%2900019-910.1016/j.cyto.2022.155810>
?:hasPublicationType	<https://research.tib.eu/covid-19/entity/Clinical_Trial%2C_Phase_III> <https://research.tib.eu/covid-19/entity/Journal_Article> <https://research.tib.eu/covid-19/entity/Randomized_Controlled_Trial>
?:journal	Cytokine
is ?:pmid of	<https://research.tib.eu/covid-19/entity/35121493>
?:pmid	<https://research.tib.eu/covid-19/entity/35121493>
?:pmid	35121493
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/Covid-19>
?:rankingScore_SJR	1.433
?:rankingScore_hIndex	99
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/C0599732_COEXISTS_WITH_C0012634> <https://research.tib.eu/covid-19/entity/C0599755_LOCATION_OF_C1424460> <https://research.tib.eu/covid-19/entity/C0870668_LOCATION_OF_C1424460>
?:title	Elevated plasma levels of CXCL16 in severe COVID-19 patients.
?:type	<https://research.tib.eu/covid-19/vocab/Publication> <https://research.tib.eu/covid-19/vocab/Publication_Author>
?:year	2022

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/35121493>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/35121493>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all